MedKoo product information:

 Clodronate disodium

clodronate disodium is the disodium salt of a nitrogen-free bisphosphonate analog of naturally occurring pyrophosphate. Clodronate binds to calcium and inhibits osteoclastic bone resorption and hydroxyapatite crystal formation and dissolution, resulting in a reduction of bone turnover. This agent may control malignancy-associated hypercalcemia, inhibit osteolytic bone metastasis and decrease pain. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Clodronic acid (INN) or clodronate disodium (USAN) is a bisphosphonate. It is used in experimental medicine to selectively deplete for macrophages. It is also approved for human use in Canada, the United Kingdom and Italy, where it is marketed as Bonefos, Loron and Clodron and prescribed as a bone resorption inhibitor and antihypercalcemic agent. (source: http://en.wikipedia.org/wiki/Clodronic_acid).

Current developer:   

 1: Kamendulis LM, Corthals SM, Klaunig JE. Kupffer cells participate in 2-butoxyethanol-induced liver hemangiosarcomas. Toxicology. 2010 Apr 11;270(2-3):131-6. Epub 2010 Feb 11. PubMed PMID: 20153399.

2: Meng Y, Beckett MA, Liang H, Mauceri HJ, van Rooijen N, Cohen KS, Weichselbaum RR. Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res. 2010 Feb 15;70(4):1534-43. Epub 2010 Feb 9. PubMed PMID: 20145121.

3: Tauchert S, di Liberto A, Cordes T, Thill M, Salehin D, Friedrich M. Tartrate-resistant acid phosphatase (TRAP) as a serum marker for bone resorption in breast cancer patients with bone metastases. Clin Exp Obstet Gynecol. 2009;36(4):219-25. PubMed PMID: 20101852.

4: McCloskey E, Paterson A, Kanis J, Tähtelä R, Powles T. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. Eur J Cancer. 2010 Feb;46(3):558-65. Epub 2009 Dec 22. PubMed PMID: 20031392.

5: Aragon-Ching JB. Further analysis of the survival benefit of clodronate. Cancer Biol Ther. 2009 Dec;8(23):2221-2. Epub 2009 Dec 30. PubMed PMID: 19855155.

6: Tauchmanova L, Guerra E, Pivonello R, De Martino MC, De Leo M, Caggiano F, Lombardi G, Colao A. Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome. J Endocrinol Invest. 2009 May;32(5):390-4. PubMed PMID: 19794285.

7: Hafeman S, London C, Elmslie R, Dow S. Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs. Cancer Immunol Immunother. 2010 Mar;59(3):441-52. Epub 2009 Sep 16. PubMed PMID: 19760220.

8: Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009 Sep;10(9):872-6. Epub 2009 Aug 10. PubMed PMID: 19674936; PubMed Central PMCID: PMC2748902.

9: Machado M, Cruz LS, Tannus G, Fonseca M. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials. Clin Ther. 2009 May;31(5):962-79. Review. PubMed PMID: 19539097.

10: Torroella-Kouri M, Silvera R, Rodriguez D, Caso R, Shatry A, Opiela S, Ilkovitch D, Schwendener RA, Iragavarapu-Charyulu V, Cardentey Y, Strbo N, Lopez DM. Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res. 2009 Jun 1;69(11):4800-9. Epub 2009 May 19. PubMed PMID: 19458073.

11: Yang DM, Teng HC, Chen KH, Tsai ML, Lee TK, Chou YC, Chi CW, Chiou SH, Lee CH. Clodronate-induced cell apoptosis in human thyroid carcinoma is mediated via the P2 receptor signaling pathway. J Pharmacol Exp Ther. 2009 Aug;330(2):613-23. Epub 2009 May 15. PubMed PMID: 19448140.

12: Coleman RE. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? Eur J Cancer. 2009 Jul;45(11):1909-15. Epub 2009 May 15. PubMed PMID: 19447606.

13: Takahashi T, Ibata M, Yu Z, Shikama Y, Endo Y, Miyauchi Y, Nakamura M, Tashiro-Yamaji J, Miura-Takeda S, Shimizu T, Okada M, Ueda K, Kubota T, Yoshida R. Rejection of intradermally injected syngeneic tumor cells from mice by specific elimination of tumor-associated macrophages with liposome-encapsulated dichloromethylene diphosphonate, followed by induction of CD11b(+)/CCR3(-)/Gr-1(-) cells cytotoxic against the tumor cells. Cancer Immunol Immunother. 2009 Dec;58(12):2011-23. Epub 2009 Apr 14. PubMed PMID: 19365632.

14: Li X, Hanson C, Cmarik JL, Ruscetti S. Neurodegeneration induced by PVC-211 murine leukemia virus is associated with increased levels of vascular endothelial growth factor and macrophage inflammatory protein 1 alpha and is inhibited by blocking activation of microglia. J Virol. 2009 May;83(10):4912-22. Epub 2009 Mar 11. PubMed PMID: 19279110; PubMed Central PMCID: PMC2682059.

15: Halin S, Rudolfsson SH, Van Rooijen N, Bergh A. Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia. 2009 Feb;11(2):177-86. PubMed PMID: 19177202; PubMed Central PMCID: PMC2631142.

16: Bartl R. [Bisphosphonates for osseus invasion caused by bronchial carcinoma]. Dtsch Med Wochenschr. 2008 Nov;133(48):2530. Epub 2008 Nov 19. German. PubMed PMID: 19021088.

17: Saarto T, Vehmanen L, Blomqvist C, Elomaa I. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. J Clin Oncol. 2008 Sep 10;26(26):4289-95. PubMed PMID: 18779616.

18: Hiraoka K, Zenmyo M, Watari K, Iguchi H, Fotovati A, Kimura YN, Hosoi F, Shoda T, Nagata K, Osada H, Ono M, Kuwano M. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci. 2008 Aug;99(8):1595-602. PubMed PMID: 18754872.

19: Carranza Lira S. [Mandible osteonechrosis associated to bisfosfonates]. Ginecol Obstet Mex. 2007 Nov;75(11):655-60. Review. Spanish. PubMed PMID: 18697439.

20: Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, Schuetz F. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol. 2008 Dec;19(12):2007-11. Epub 2008 Jul 29. PubMed PMID: 18664560; PubMed Central PMCID: PMC2733118.

21: Paterson A, McCloskey E, Redzepovic J, Ott I, Gust R. Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients. J Int Med Res. 2008 May-Jun;36(3):400-13. PubMed PMID: 18534121.

22: Banciu M, Schiffelers RM, Storm G. Investigation into the role of tumor-associated macrophages in the antitumor activity of Doxil. Pharm Res. 2008 Aug;25(8):1948-55. Epub 2008 Jun 4. PubMed PMID: 18523874; PubMed Central PMCID: PMC2469273.

23: Soltau J, Zirrgiebel U, Esser N, Schächtele C, Totzke F, Unger C, Merfort I, Drevs J. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res. 2008 Mar-Apr;28(2A):933-41. PubMed PMID: 18507039.

24: Cafro AM, Barbarano L, Nosari AM, D'Avanzo G, Nichelatti M, Bibas M, Gaglioti D, Taroni A, Riva F, Morra E, Andriani A. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid. Clin Lymphoma Myeloma. 2008 Apr;8(2):111-6. Erratum in: Clin Lymphoma Myeloma. 2008 Aug;8(4):260. Barbarano, Luciana [added]; Nosari, Anna Maria [added]; D'Avanzo, Giovanna [added]; Nichelatti, Michele [added]; Bibas, Michele [added]; Gaglioti, Domenico [added]; Taroni, Alberto [added]; Riva, Francesco [added]; Morra, Enrica [added]; Andriani, Alessandro [added]. PubMed PMID: 18501105.

25: Mönkkönen H, Kuokkanen J, Holen I, Evans A, Lefley DV, Jauhiainen M, Auriola S, Mönkkönen J. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs. 2008 Apr;19(4):391-9. PubMed PMID: 18454049.

26: Menon C, Bauer TW, Kelley ST, Raz DJ, Bleier JI, Patel K, Steele K, Prabakaran I, Shifrin A, Buerk DG, Sehgal CM, Fraker DL. Tumoricidal activity of high-dose tumor necrosis factor-alpha is mediated by macrophage-derived nitric oxide burst and permanent blood flow shutdown. Int J Cancer. 2008 Jul 15;123(2):464-75. PubMed PMID: 18449880.

27: Ribatti D, Maruotti N, Nico B, Longo V, Mangieri D, Vacca A, Cantatore FP. Clodronate inhibits angiogenesis in vitro and in vivo. Oncol Rep. 2008 May;19(5):1109-12. PubMed PMID: 18425365.

28: Udvardy E, Redl P, Márton I. [Osteonecrosis of the jaw developing during bisphosphonate treatment]. Magy Onkol. 2008 Mar;52(1):81-7. Review. Hungarian. PubMed PMID: 18403302.

29: Miselis NR, Wu ZJ, Van Rooijen N, Kane AB. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther. 2008 Apr;7(4):788-99. Epub 2008 Mar 28. PubMed PMID: 18375821.

30: Banciu M, Metselaar JM, Schiffelers RM, Storm G. Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. Neoplasia. 2008 Feb;10(2):108-17. PubMed PMID: 18283332; PubMed Central PMCID: PMC2244685.

31: Kimura YN, Watari K, Fotovati A, Hosoi F, Yasumoto K, Izumi H, Kohno K, Umezawa K, Iguchi H, Shirouzu K, Takamori S, Kuwano M, Ono M. Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci. 2007 Dec;98(12):2009-18. Epub 2007 Oct 9. PubMed PMID: 17924976.

32: Brown JE, McCloskey EV, Dewar JA, Body JJ, Cameron DA, Harnett AN, Ruutu M, Purohit OP, Tähtelä R, Coleman RE. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease. Calcif Tissue Int. 2007 Nov;81(5):341-51. Epub 2007 Sep 18. PubMed PMID: 17874331.

33: Montazeri AH, Erskine JG, McQuaker IG. Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Eur J Haematol. 2007 Jul;79(1):69-71. PubMed PMID: 17598839.

34: Pritchard KI. Bisphosphonates: are they standard of care for the treatment of breast cancer? Br J Cancer. 2007 Jun 18;96(12):1781-2. PubMed PMID: 17565339; PubMed Central PMCID: PMC2359974.

35: Papagni S, Mongelli N, Cozzolino M, Brancaccio D, Ciccolella F, Favia G. [Avascular jaw osteonecrosis in a hemodialysis patient treated with bisphosphonates.]. G Ital Nefrol. 2007 May-Jun;24(3):230-4. Italian. PubMed PMID: 17554735.

36: Mason MD, Sydes MR, Glaholm J, Langley RE, Huddart RA, Sokal M, Stott M, Robinson AC, James ND, Parmar MK, Dearnaley DP; Medical Research Council PR04 Collaborators. Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst. 2007 May 16;99(10):765-76. PubMed PMID: 17505072.

37: Rodrigues P, Hering FO, Bruna P, Meller A, Afonso Y. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study. Int J Urol. 2007 Apr;14(4):317-20. PubMed PMID: 17470161.

38: Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A, Mantovani A, Mordoh J, Wainstok R. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol. 2007 Aug;127(8):2031-41. Epub 2007 Apr 26. PubMed PMID: 17460736.

39: Dalle Carbonare L, Valenti MT, Bertoldo F, Fracalossi A, Balducci E, Azzarello G, Vinante O, Lo Cascio V. Amino-bisphosphonates decrease hTERT gene expression in breast cancer in vitro. Aging Clin Exp Res. 2007 Apr;19(2):91-6. PubMed PMID: 17446718.

40: Grötz KA, Walter C, Küttner C, Al-Nawas B. [Relevance of bisphosphonate long-term therapy in radiation therapy of endosteal jaw metastases]. Strahlenther Onkol. 2007 Apr;183(4):190-4. German. PubMed PMID: 17406800.

41: Verì A, D'Andrea MR, Bonginelli P, Gasparini G. Clinical usefulness of bisphosphonates in oncology: treatment of bone metastases, antitumoral activity and effect on bone resorption markers. Int J Biol Markers. 2007 Jan-Mar;22(1):24-33. Review. PubMed PMID: 17393358.

42: Kraj M, Pogłód R, Maj S, Owczarska K. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates. Acta Pol Pharm. 2006 Sep-Oct;63(5):450-2. PubMed PMID: 17357613.

43: Mocanu JD, Yip KW, Alajez NM, Shi W, Li JH, Lunt SJ, Moriyama EH, Wilson BC, Milosevic M, Lo KW, van Rooijen N, Busson P, Bastianutto C, Liu FF. Imaging the modulation of adenoviral kinetics and biodistribution for cancer gene therapy. Mol Ther. 2007 May;15(5):921-9. Epub 2007 Mar 13. PubMed PMID: 17356543.

44: Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer. 2007 Jun 18;96(12):1796-801. Epub 2007 Feb 27. PubMed PMID: 17325699; PubMed Central PMCID: PMC2359972.

45: Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst. 2007 Feb 21;99(4):322-30. PubMed PMID: 17312309.

46: Senel FC, Saracoglu Tekin U, Durmus A, Bagis B. Severe osteomyelitis of the mandible associated with the use of non-nitrogen-containing bisphosphonate (disodium clodronate): report of a case. J Oral Maxillofac Surg. 2007 Mar;65(3):562-5. PubMed PMID: 17307610.

47: Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol. 2006 Oct 20;24(30):4895-900. Epub 2006 Sep 25. PubMed PMID: 17001071.

48: Wang CH, Shen YC, Hsieh JJ, Yeh KY, Chang JW. Clodronate alleviates cachexia and prolongs survival in nude mice xenografted with an anaplastic thyroid carcinoma cell line. J Endocrinol. 2006 Aug;190(2):415-23. PubMed PMID: 16899574.

49: Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjällman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer. 2006 Aug 7;95(3):272-81. Epub 2006 Jul 11. PubMed PMID: 16832418; PubMed Central PMCID: PMC2360657.

50: Boonman ZF, Schurmans LR, van Rooijen N, Melief CJ, Toes RE, Jager MJ. Macrophages are vital in spontaneous intraocular tumor eradication. Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2959-65. PubMed PMID: 16799039.

51: Verdijk R, Franke HR, Wolbers F, Vermes I. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett. 2007 Feb 8;246(1-2):308-12. Epub 2006 Apr 18. PubMed PMID: 16621245.

52: Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 2006;8(2):R13. Epub 2006 Mar 15. Erratum in: Breast Cancer Res. 2006;8(3):406. PubMed PMID: 16542503; PubMed Central PMCID: PMC1557723.

53: S0307. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer. Clin Adv Hematol Oncol. 2005 Nov;3(11):852-4. PubMed PMID: 16491627.

54: Caffo O. [Zoledronic acid and bone pathology in the course of neoplasia. Part I]. Tumori. 2005 Sep-Oct;91(5):22-6. Review. Italian. PubMed PMID: 16459649.

55: Santangelo A, Testai M, Barbagallo P, Manuele S, Di Stefano A, Tomarchio M, Trizzino G, Musumeci G, Panebianco P, Maugeri D. The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population. Arch Gerontol Geriatr. 2006 Sep-Oct;43(2):187-92. Epub 2005 Dec 2. PubMed PMID: 16325938.

56: Knight LA, Conroy M, Fernando A, Polak M, Kurbacher CM, Cree IA. Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay. Anticancer Drugs. 2005 Oct;16(9):969-76. PubMed PMID: 16162973.

57: Pino Rivero V, Trinidad Ruiz G, Pardo Romero G, Pantoja Hernández CG, González Palomino A, Marcos García M, Keituqwa Yáñez T, Blasco Huelva A. [Association between primary hyperparathyroidism and Paget's disease. Report of a case]. An Otorrinolaringol Ibero Am. 2005;32(4):317-22. Spanish. PubMed PMID: 16156361.

58: Markovic DS, Glass R, Synowitz M, Rooijen N, Kettenmann H. Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J Neuropathol Exp Neurol. 2005 Sep;64(9):754-62. PubMed PMID: 16141784.

59: Saarto T, Taube T, Blomqvist C, Vehmanen L, Elomaa I. Three-year oral clodronate treatment does not impair mineralization of newly formed bone--a histomorphometric study. Calcif Tissue Int. 2005 Aug;77(2):84-90. Epub 2005 Aug 11. PubMed PMID: 16075363.

60: Dalle Carbonare L, Valenti MT, Azzarello G, Balducci E, Crepaldi G, Realdi G, Vinante O, Giannini S. Bisphosphonates decrease telomerase activity and hTERT expression in MCF-7 breast cancer cells. Mol Cell Endocrinol. 2005 Aug 30;240(1-2):23-31. PubMed PMID: 15978718.

61: Gulley J, Dahut WL. Clodronate in the prevention and treatment of skeletal metastasis. Expert Rev Anticancer Ther. 2005 Apr;5(2):221-30. Review. PubMed PMID: 15877520.

62: Lugassy G. "Safety and convenience of a 15-minute infusion of zoledronic acid": not so safe. Oncologist. 2005 May;10(5):309-10; author reply 311-2. PubMed PMID: 15851782.

63: Balla J. The issue of renal safety of zoledronic acid from a nephrologist's point of view. Oncologist. 2005 May;10(5):306-8; author reply 311-2. PubMed PMID: 15851781.

64: Paterson AH. Adjuvant clodronate in breast cancer. Acta Oncol. 2005;44(1):80-2; author reply 83-4. PubMed PMID: 15848910.

65: Parker CC. The role of bisphosphonates in the treatment of prostate cancer. BJU Int. 2005 May;95(7):935-8. Review. PubMed PMID: 15839907.

66: Clemons M, Verma S. Should oral bisphosphonates be standard of care in women with early breast cancer? Breast Cancer Res Treat. 2005 Apr;90(3):315-8. Review. PubMed PMID: 15830146.

67: Gralow J. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer. Clin Breast Cancer. 2005 Feb;5 Suppl(2):S54-62. Review. PubMed PMID: 15807925.

68: Leppä S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer. Breast Cancer Res Treat. 2005 Mar;90(2):117-25. PubMed PMID: 15803358.

69: Coleman RE. Bisphosphonates in breast cancer. Ann Oncol. 2005 May;16(5):687-95. Epub 2005 Mar 31. Review. PubMed PMID: 15802276.

70: Ozyuvaci E, Altan A, Demir C. [The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer]. Agri. 2005 Jan;17(1):49-53. Turkish. PubMed PMID: 15791501.

71: Saba N, Khuri F. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications. Oncology. 2005;68(1):10-7. Epub 2004 Mar 15. Review. PubMed PMID: 15775688.

72: Longo F, Mansueto G. [AIOM Conference 2004. Endocrine therapy and management of patients with bone metastasis of breast cancer]. Tumori. 2004 Nov-Dec;90(6):1-12. Italian. PubMed PMID: 15762372.

73: Kamby C, Pedersen L, Kristensen B. [Diphosphonates in solid malignant tumors]. Ugeskr Laeger. 2005 Jan 24;167(4):379-82. Review. Danish. PubMed PMID: 15719560.

74: Svishchenko IuA, Shimanovskiĭ NL. [Expanding the possibilities of using biphosphonates for prophylaxis and treatment of osteal complications in malignant metastasis]. Eksp Klin Farmakol. 2004 Nov-Dec;67(6):66-71. Review. Russian. PubMed PMID: 15707020.

75: Delanian S, Depondt J, Lefaix JL. Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial. Head Neck. 2005 Feb;27(2):114-23. PubMed PMID: 15641107.

76: Dando TM, Wiseman LR. Clodronate : a review of its use in the prevention of bone metastases and the management of skeletal complications associated with bone metastases in patients with breast cancer. Drugs Aging. 2004;21(14):949-62. Review. PubMed PMID: 15554753.

77: Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 2004;43(7):650-6. PubMed PMID: 15545185.

78: Rodrigues P, Hering F, Campagnari JC. Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients. Prostate Cancer Prostatic Dis. 2004;7(4):350-4. PubMed PMID: 15534620.

79: Vorotnjak M, Boos J, Lanvers-Kaminsky C. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines. Anticancer Drugs. 2004 Sep;15(8):795-802. PubMed PMID: 15494642.

80: Conte P, Coleman R. Bisphosphonates in the treatment of skeletal metastases. Semin Oncol. 2004 Oct;31(5 Suppl 10):59-63. Review. PubMed PMID: 15490377.

81: Journe F, Chaboteaux C, Dumon JC, Leclercq G, Laurent G, Body JJ. Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells. Br J Cancer. 2004 Nov 1;91(9):1703-10. PubMed PMID: 15477866; PubMed Central PMCID: PMC2409948.

82: Wietrzyk J, Pełczyńska M, Madej J, Dzimira S, Kuśnierczyk H, Kutner A, Szelejewski W, Opolski A. Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191). Steroids. 2004 Sep;69(10):629-35. PubMed PMID: 15465107.

83: Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med. 2004 Sep 15;117(6):440-1. PubMed PMID: 15380503.

84: Vehmanen L, Saarto T, Risteli J, Risteli L, Blomqvist C, Elomaa I. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat. 2004 Sep;87(2):181-8. PubMed PMID: 15377842.

85: Forsea AM, Müller C, Riebeling C, Orfanos CE, Geilen CC. Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells. Br J Cancer. 2004 Aug 16;91(4):803-10. PubMed PMID: 15280922; PubMed Central PMCID: PMC2364766.

86: Yang DM, Chi CW, Chang HM, Wu LH, Lee TK, Lin JD, Chen ST, Lee CH. Effects of clodronate on cancer growth and Ca2+ signaling of human thyroid carcinoma cell lines. Anticancer Res. 2004 May-Jun;24(3a):1617-23. PubMed PMID: 15274331.

87: Vehmanen L, Saarto T, Blomqvist C, Taskinen MR, Elomaa I. Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids. Br J Cancer. 2004 Aug 2;91(3):476-81. PubMed PMID: 15266329; PubMed Central PMCID: PMC2409844.

88: Romanus D, Iscoe N, Deangelis C, Shear N, Einarson TR. Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients. Support Care Cancer. 2004 Dec;12(12):844-51. Epub 2004 Jul 3. PubMed PMID: 15235902.

89: Palmieri C, Dhillon T, Coombes C, Vigushin D. Hypocalcaemia after intravenous bisphosphonate: adjuvant bisphosphonate is not currently accepted practice. BMJ. 2004 Jun 12;328(7453):1439; author reply 1439-40. PubMed PMID: 15191993; PubMed Central PMCID: PMC421835.

90: Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid. Oncologist. 2004;9(3):319-29. Review. PubMed PMID: 15169987.

91: Hershman D, Narayanan R. Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer. Curr Oncol Rep. 2004 Jul;6(4):277-84. Review. PubMed PMID: 15161581.

92: Atula ST, Tähtelä RK, Nevalainen JI, Pylkkänen LH. Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia. Acta Oncol. 2003;42(7):735-40. PubMed PMID: 14690159.

93: Ivanov SD, Iamshanov VA, Korytova LI, Khazova TV, Arzumanov AS. [Prognostication of hematotoxicity for radio- and chemotherapy in patients with breast cancer]. Vopr Onkol. 2003;49(5):601-7. Russian. PubMed PMID: 14682132.

94: Lipton A. Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs. 2003 Nov;8(2):469-88. Review. PubMed PMID: 14662000.

95: Smith MR. Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer. J Urol. 2003 Dec;170(6 Pt 2):S55-7; discussion S57-8. Review. PubMed PMID: 14610411.

96: Cameron DA. Should all adjuvant breast cancer patients receive a bisphosphonate? Breast Cancer Res. 2003;5(6):296-9. Epub 2003 Oct 1. PubMed PMID: 14580244; PubMed Central PMCID: PMC314408.

97: Enright K, Clemons M, Chow E. Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience. Support Care Cancer. 2004 Jan;12(1):48-52. Epub 2003 Oct 24. PubMed PMID: 14577020.

98: Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in vitro. Anticancer Drugs. 2003 Oct;14(9):767-71. PubMed PMID: 14551512.

99: Roemer-Bécuwe C, Vigano A, Romano F, Neumann C, Hanson J, Quan HK, Walker P. Safety of subcutaneous clodronate and efficacy in hypercalcemia of malignancy: a novel route of administration. J Pain Symptom Manage. 2003 Sep;26(3):843-8. PubMed PMID: 12967733.

100: Valleala H, Hanemaaijer R, Mandelin J, Salminen A, Teronen O, Mönkkönen J, Konttinen YT. Regulation of MMP-9 (gelatinase B) in activated human monocyte/macrophages by two different types of bisphosphonates. Life Sci. 2003 Sep 26;73(19):2413-20. Erratum in: Life Sci. 2004 Jun 4;75(3):381. PubMed PMID: 12954450.

101: Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, Thompson PM, Moffat LE, Naylor SL, Parmar MK; Mrc Pr05 Collaborators. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst. 2003 Sep 3;95(17):1300-11. PubMed PMID: 12953084.

102: Bankhead C. Clinical trials test bisphosphonates in hormone-sensitive prostate cancer. J Natl Cancer Inst. 2003 Sep 3;95(17):1273-4. PubMed PMID: 12953081.

103: Saad F. Bisphosphonates in prostate cancer: where are we and where should we go? J Natl Cancer Inst. 2003 Sep 3;95(17):1262-3. PubMed PMID: 12953073.

104: Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003 Sep 1;21(17):3335-42. PubMed PMID: 12947070.

105: Bezzi M, Hasmim M, Bieler G, Dormond O, Rüegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem. 2003 Oct 31;278(44):43603-14. Epub 2003 Aug 20. PubMed PMID: 12933798.

106: Heikkilä P, Teronen O, Hirn MY, Sorsa T, Tervahartiala T, Salo T, Konttinen YT, Halttunen T, Moilanen M, Hanemaaijer R, Laitinen M. Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate. J Surg Res. 2003 May 1;111(1):45-52. PubMed PMID: 12842447.

107: Atula S, Powles T, Paterson A, McCloskey E, Nevalainen J, Kanis J. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf. 2003;26(9):661-71. PubMed PMID: 12814333.

108: Rivas C, Djeraba A, Musset E, van Rooijen N, Baaten B, Quéré P. Intravenous treatment with liposome-encapsulated dichloromethylene bisphosphonate (Cl2MBP) suppresses nitric oxide production and reduces genetic resistance to Marek's disease. Avian Pathol. 2003 Apr;32(2):139-49. PubMed PMID: 12745367.

109: Ashcroft AJ, Davies FE, Morgan GJ. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol. 2003 May;4(5):284-92. Review. PubMed PMID: 12732166.

110: Yoshioka S, Tsujinaka T, Kida H, Hirao M, Fujitani K. [A patient with gastric cancer complicated with severe DIC and multiple bone metastasis showing a high response to combination of TS-1 and CDDP]. Gan To Kagaku Ryoho. 2003 Mar;30(3):403-6. Japanese. PubMed PMID: 12669401.

111: Nishimura K, Takahara S, Nonomura N, Okuyama A. [Therapy for hormone-refractory prostate cancer]. Nippon Rinsho. 2002 Dec;60 Suppl 11:266-71. Review. Japanese. PubMed PMID: 12599583.

112: Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol. 2002 Dec;29(6 Suppl 21):12-8. Review. PubMed PMID: 12584690.

113: Lastůvková I, Adam Z. [A questionnaire survey of tolerance and adverse effects of clodronate (Bonefos) in patients with multiple myeloma]. Vnitr Lek. 2002 Nov;48(11):1049-53. Czech. PubMed PMID: 12577456.

114: Horváth Z. [The role of adjuvant clodronate therapy for prevention of bone metastasis in breast cancer]. Magy Onkol. 2002;46(4):361-4. Epub 2003 Feb 1. Review. Hungarian. PubMed PMID: 12563361.

115: Major PP, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol. 2002 Dec;25(6 Suppl 1):S10-8. Review. PubMed PMID: 12562046.

116: Coleman RE. Current and future status of adjuvant therapy for breast cancer. Cancer. 2003 Feb 1;97(3 Suppl):880-6. Review. PubMed PMID: 12548590.

117: Barthel HR. Bisphosphonates for RSDS and prostate cancer--more benefit then revealed! Joint Bone Spine. 2002 Oct;69(5):521; author reply 522. PubMed PMID: 12477242.

118: Walker K, Medhurst SJ, Kidd BL, Glatt M, Bowes M, Patel S, McNair K, Kesingland A, Green J, Chan O, Fox AJ, Urban LA. Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. Pain. 2002 Dec;100(3):219-29. PubMed PMID: 12467993.

119: Jantunen E. Bisphosphonate therapy in multiple myeloma: past, present, future. Eur J Haematol. 2002 Nov-Dec;69(5-6):257-64. Review. PubMed PMID: 12460229.

120: Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clézardin P. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002 Nov 15;62(22):6538-44. PubMed PMID: 12438248.

121: Ghinoi V, Brandi ML. Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders. Expert Opin Pharmacother. 2002 Nov;3(11):1643-56. Review. PubMed PMID: 12437497.

122: Gralow JR. Bisphosphonates as adjuvant treatment for breast cancer. BMJ. 2002 Nov 9;325(7372):1051-2. PubMed PMID: 12424151; PubMed Central PMCID: PMC1124564.

123: Fassnacht M, Franke A, Dettling A, Hahner S, Zink M, Wudy S, Allolio B. Clodronate inhibits adrenocortical cell proliferation and P450c21 activity. J Endocrinol. 2002 Sep;174(3):509-16. PubMed PMID: 12208672.

124: Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS; American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002 Sep 1;20(17):3719-36. PubMed PMID: 12202673.

125: Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Männistö E, Suovuori A, Atula S, Nevalainen J, Pylkkänen L. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002 Aug 1;20(15):3219-24. PubMed PMID: 12149294.

126: Mundy GR. Bisphosphonates and tumor burden. J Clin Oncol. 2002 Aug 1;20(15):3191-2. PubMed PMID: 12149289.

127: Elomaa I, Saarto T. [Use of clodronate in the adjuvant treatment of breast cancer is questionable for the time being]. Duodecim. 2001;117(10):1021-2. Finnish. PubMed PMID: 12116460.

128: Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev. 2002;(2):CD002068. Review. PubMed PMID: 12076438.

129: Adam Z. [Is pamidronate or clodronate better?]. Vnitr Lek. 2002 Apr;48(4):357. Czech. PubMed PMID: 12075601.

130: Delanian S, Lefaix JL. Complete healing of severe osteoradionecrosis with treatment combining pentoxifylline, tocopherol and clodronate. Br J Radiol. 2002 May;75(893):467-9. PubMed PMID: 12036843.

131: Virtanen SS, Väänänen HK, Härkönen PL, Lakkakorpi PT. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res. 2002 May 1;62(9):2708-14. PubMed PMID: 11980672.

132: Shah S, Hardy J, Rees E, Ling J, Gwilliam B, Davis C, Broadley K, A'Hern R. Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia? Br J Cancer. 2002 Apr 22;86(8):1235-7. PubMed PMID: 11953878; PubMed Central PMCID: PMC2375352.

133: Stajszczyk M, Mykała-Cieśla J. [Bisphosphonates in the treatment of breast carcinoma]. Pol Arch Med Wewn. 2001 Aug;106(2):729-38. Review. Polish. PubMed PMID: 11926150.

134: Diel IJ, Solomayer EF, Bastert G. Treatment of metastatic bone disease in breast cancer: bisphosphonates. Clin Breast Cancer. 2000 Apr;1(1):43-51. Review. PubMed PMID: 11899389.

135: Pelger RC, Soerdjbalie-Maikoe V, Hamdy NA. Strategies for management of prostate cancer-related bone pain. Drugs Aging. 2001;18(12):899-911. Review. PubMed PMID: 11888345.

136: Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol. 2001 Oct;12(10):1433-8. PubMed PMID: 11762816.

137: Vehmanen L, Saarto T, Elomaa I, Mäkelä P, Välimäki M, Blomqvist C. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer. 2001 Dec;37(18):2373-8. PubMed PMID: 11720830.

138: Paterson AH. Adjuvant bisphosphonate therapy: the future. Semin Oncol. 2001 Aug;28(4 Suppl 11):81-5. Review. PubMed PMID: 11544582.

139: Diel IJ. Bisphosphonates in the prevention of bone metastases: current evidence. Semin Oncol. 2001 Aug;28(4 Suppl 11):75-80. Review. PubMed PMID: 11544581.

140: Tjalma WA, Buytaert PM, Berneman ZN. Reduction of visible bone metastases by clodronate therapy in breast cancer. Eur J Gynaecol Oncol. 2001;22(3):215-6. PubMed PMID: 11501775.

141: Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A, Pion JM, Switsers O, Misset JL, Assadourian S, Bessa E. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]. Bull Cancer. 2001 Jul;88(7):701-7. French. PubMed PMID: 11495824.

142: Jones J. Bisphosphonates may be useful in treatment of bone metastases. J Natl Cancer Inst. 2001 Jul 18;93(14):1052-3. PubMed PMID: 11459865.

143: McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol. 2001 Jun;113(4):1035-43. PubMed PMID: 11442499.

144: Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs. 2001 Jun;12(5):459-65. PubMed PMID: 11395574.

145: Tomíska M, Adam Z, Prokes B, Dusek L, Hájek R, Vorlícek J. Bone mineral density in multiple myeloma patients after intravenous clodronate therapy. Acta Med Austriaca. 2001;28(2):38-42. PubMed PMID: 11382140.

146: Saarto T, Vehmanen L, Elomaa I, Välimäki M, Mäkelä P, Blomqvist C. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer. 2001 Apr 20;84(8):1047-51. PubMed PMID: 11308252; PubMed Central PMCID: PMC2363866.

147: Johnson IS. Use of bisphosphonates for the treatment of metastatic bone pain. A survey of palliative physicians in the UK. Palliat Med. 2001 Mar;15(2):141-7. PubMed PMID: 11301665.

148: Everse LA, Anderson LD Jr, van Rooijen N, Mullen CA. Bone marrow transplant conditioning intensified with liposomal clodronate to eliminate residual host antigen presenting cells fails to ameliorate GVHD and increases PERI-BMT mortality. Transplantation. 2001 Mar 15;71(5):611-8. PubMed PMID: 11292289.

149: Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer. 2001 Apr 6;84(7):951-8. PubMed PMID: 11286476; PubMed Central PMCID: PMC2363848.

150: Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001 Jan 1;19(1):10-7. PubMed PMID: 11134190.

151: Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol. 2001 Jan;165(1):136-40. PubMed PMID: 11125382.

152: Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res. 2000 Nov;15(11):2211-21. PubMed PMID: 11092402.

153: Mardiak J, Bohunický L, Chovanec J, Sálek T, Koza I. Adjuvant clodronate therapy in patients with locally advanced breast cancer--long term results of a double blind randomized trial. Slovak Clodronate Collaborative Group. Neoplasma. 2000;47(3):177-80. PubMed PMID: 11043842.

154: Clark RE, Flory AJ, Ion EM, Woodcock BE, Durham BH, Fraser WD. Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. Blood. 2000 Oct 15;96(8):2697-702. PubMed PMID: 11023500.

155: Schilbach KE, Geiselhart A, Wessels JT, Niethammer D, Handgretinger R. Human gammadelta T lymphocytes exert natural and IL-2-induced cytotoxicity to neuroblastoma cells. J Immunother. 2000 Sep-Oct;23(5):536-48. PubMed PMID: 11001547.

156: Diel IJ, Solomayer EF, Bastert G. Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer. 2000 Jun 15;88(12 Suppl):3080-8. Review. PubMed PMID: 10898355.

157: Body JJ. Current and future directions in medical therapy: hypercalcemia. Cancer. 2000 Jun 15;88(12 Suppl):3054-8. Review. PubMed PMID: 10898351.

158: Kanis JA, McCloskey EV. Bisphosphonates in multiple myeloma. Cancer. 2000 Jun 15;88(12 Suppl):3022-32. Review. PubMed PMID: 10898347.

159: Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaissé JM, Clézardin P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000 Jun 1;60(11):2949-54. PubMed PMID: 10850442.

160: Paule B, Clerc D, Brion N. [Biosphonates in oncology]. Presse Med. 2000 Apr 8;29(13):723-9. French. PubMed PMID: 10797827.

161: Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000 Apr;82(8):1459-68. PubMed PMID: 10780527; PubMed Central PMCID: PMC2363380.

162: Ranganath L, Semple MJ. Hypercalcaemia in a 63 year old man. Postgrad Med J. 2000 May;76(895):309-10, 313-4. PubMed PMID: 10775292; PubMed Central PMCID: PMC1741577.

163: Ciray I, Aström G, Andréasson I, Edekling T, Hansen J, Bergh J, Ahlström H. Evaluation of new sclerotic bone metastases in breast cancer patients during treatment. Acta Radiol. 2000 Mar;41(2):178-82. PubMed PMID: 10741794.

164: Serkies K, Jereczek-Fossa B, Badzio A, Jassem J. Clodronate in the management of bone metastases: a clinical study of 91 patients. Neoplasma. 1999;46(5):317-22. PubMed PMID: 10665850.

165: Major PP, Lipton A, Berenson J, Hortobagyi G. Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer. 2000 Jan 1;88(1):6-14. Review. PubMed PMID: 10618600.

166: Arican A, Içli F, Akbulut H, Cakir M, Sencan O, Samur M, Açikgöz N, Demirkazik A. The effect of two different doses of oral clodronate on pain in patients with bone metastases. Med Oncol. 1999 Sep;16(3):204-10. PubMed PMID: 10523801.

167: Lortholary A, Jadaud E, Berthaud P. [Bisphosphonates and bone metastases]. Bull Cancer. 1999 Sep;86(9):732-8. Review. French. PubMed PMID: 10519966.

168: Hurst M, Noble S. Clodronate: a review of its use in breast cancer. Drugs Aging. 1999 Aug;15(2):143-67. Review. PubMed PMID: 10495073.

169: Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med. 1999 Jul;246(1):67-74. PubMed PMID: 10447227.

170: Poliakov PIu, Larionova NA, Bychenkov OA, Moc'kin VG. [An experience with combined therapy of radiation and Bonephos for osteolytic metastases of breast cancer]. Vopr Onkol. 1999;45(3):311-3. Russian. PubMed PMID: 10443239.

171: Ylitalo P, Holli K, Mönkkönen J, Elo HA, Juhakoski A, Liukko-Sipi S, Ylitalo R. Comparison of pharmacokinetics of clodronate after single and repeated doses. Int J Clin Pharmacol Ther. 1999 Jun;37(6):294-300. PubMed PMID: 10395121.

172: Califano L, Zupi A, Maremonti P, Longo F, Mangone GM, Marinelli A. [Pathological fracture of the mandible: a report of a clinical case treated with clodronate]. G Chir. 1999 Jun-Jul;20(6-7):307-9. Review. Italian. PubMed PMID: 10390927.

173: No value of oral clodronic acid in malignant osteolysis. Prescrire Int. 1998 Aug;7(36):104. PubMed PMID: 10342946.

174: Mundy GR. Bisphosphonates as cancer drugs. Hosp Pract (Minneap). 1999 May 15;34(5):81-4, 88-9, 93-4. Review. PubMed PMID: 10340036.

175: Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer. 1999 Mar;79(7-8):1179-81. PubMed PMID: 10098755; PubMed Central PMCID: PMC2362233.

176: Moiseenko VM, Blinov NN, Semiglazov VV, Konstantinova MM, Trishkina EA. [Randomized trial of two administration schedule of bonephos (Clodronate) in patients with painful bone metastasis]. Vopr Onkol. 1998;44(6):725-8. Russian. PubMed PMID: 10087976.

177: Bruce NJ, McCloskey EV, Kanis JA, Guest JF. Economic impact of using clodronate in the management of patients with multiple myeloma. Br J Haematol. 1999 Feb;104(2):358-64. PubMed PMID: 10050720.

178: Musto P. The role of bisphosphonates for the treatment of bone disease in multiple myeloma. Leuk Lymphoma. 1998 Nov;31(5-6):453-62. Review. PubMed PMID: 9922036.

179: Atkins CD. Clodronate in metastatic breast cancer. N Engl J Med. 1998 Dec 24;339(26):1941. PubMed PMID: 9874609.

180: Panasci LC, Sandor V, Melnychuk D. Clodronate in metastatic breast cancer. N Engl J Med. 1998 Dec 24;339(26):1940-1; author reply 1941. PubMed PMID: 9874608.

181: Meli M, Rausa L. Clodronate in metastatic breast cancer. N Engl J Med. 1998 Dec 24;339(26):1940; author reply 1941. PubMed PMID: 9874607.

182: Hala K, Moore C, Plachy J, Kaspers B, Böck G, Hofmann A. Genes of chicken MHC regulate the adherence activity of blood monocytes in Rous sarcomas progressing and regressing lines. Vet Immunol Immunopathol. 1998 Nov 24;66(2):143-57. PubMed PMID: 9860187.

183: Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AH, Rubens RD. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol. 1998 Dec;16(12):3890-9. Review. PubMed PMID: 9850035.

184: Diel IJ. [Bisphosphonates in the adjuvant therapy of breast cancer-- pathophysiology, animal models, and clinical experiences]. Gynakol Geburtshilfliche Rundsch. 1998;38(2):64-71. Review. German. PubMed PMID: 9815520.

185: Phillips E, Knowles S, Weber E, Shear NH. Skin reactions associated with bisphosphonates: a report of 3 cases and an approach to management. J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):697-8. PubMed PMID: 9802383.

186: Lipton A. Aredia: the once-monthly infusion for the treatment of bone metastases. Curr Opin Oncol. 1998 Aug;10 Suppl 1:S1-5. Review. PubMed PMID: 9801852.

187: Califano L, Zupi A, Maremonti P. Pathological fracture of the mandible treated with diphosphonates. Br J Oral Maxillofac Surg. 1998 Aug;36(4):319. PubMed PMID: 9762465.

188: Derrane M. Bisphosphonates: lingering questions about their use. J Natl Cancer Inst. 1998 Sep 16;90(18):1329-31. PubMed PMID: 9747862.

189: Minimizing breast cancer's spread. Health News. 1998 Sep 10;4(11):6. PubMed PMID: 9745391.

190: Busch M, Rave-Fränk M, Hille A, Dühmke E. Influence of clodronate on breast cancer cells in vitro. Eur J Med Res. 1998 Sep 17;3(9):427-31. PubMed PMID: 9737889.

191: Magnusson P, Larsson L, Englund G, Larsson B, Strang P, Selin-Sjögren L. Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain. Clin Chem. 1998 Aug;44(8 Pt 1):1621-8. PubMed PMID: 9702948.

192: Piga A, Bracci R, Ferretti B, Sandri P, Nortilli R, Acito L, Pancotti A, Di Furia L, Carle F, Cellerino R. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J Exp Clin Cancer Res. 1998 Jun;17(2):213-7. PubMed PMID: 9700583.

193: Mundy GR, Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med. 1998 Aug 6;339(6):398-400. PubMed PMID: 9691109.

194: Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998 Aug 6;339(6):357-63. PubMed PMID: 9691101.

195: Saarto T, Blomqvist C, Risteli J, Risteli L, Sarna S, Elomaa I. Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients. Br J Cancer. 1998 Jul;78(2):240-5. PubMed PMID: 9683300; PubMed Central PMCID: PMC2062893.

196: Kylmälä T. Prostate cancer and bone metastases. The effect of clodronate. Ann Chir Gynaecol. 1998;87(1):59-60. PubMed PMID: 9598233.

197: Powles TJ, McCloskey E, Paterson AH, Ashley S, Tidy VA, Nevantaus A, Rosenqvist K, Kanis J. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998 May 6;90(9):704-8. PubMed PMID: 9586668.

198: Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol. 1998 Mar;16(3):1218-25. Review. PubMed PMID: 9508210.

199: Strang P, Nilsson S, Brändstedt S, Sehlin J, Borghede G, Varenhorst E, Bandman U, Borck L, Englund G, Selin L. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res. 1997 Nov-Dec;17(6D):4717-21. PubMed PMID: 9494595.

200: Johnson MJ, Fallon MT. Symptomatic hypocalcemia with oral clodronate. J Pain Symptom Manage. 1998 Feb;15(2):140-2. PubMed PMID: 9494315.

201: McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol. 1998 Feb;100(2):317-25. PubMed PMID: 9488619.

202: Heidenreich A. [Treatment of hormone-refractive prostatic carcinoma with painful bone metastasis. Epirubicin vs. clodronate vs. epirubicin plus clodronate]. Urologe A. 1997 Nov;36(6):568. German. PubMed PMID: 9487597.

203: Adami S. Bisphosphonates in prostate carcinoma. Cancer. 1997 Oct 15;80(8 Suppl):1674-9. Review. PubMed PMID: 9362435.

204: Lipton A. Bisphosphonates and breast carcinoma. Cancer. 1997 Oct 15;80(8 Suppl):1668-73. Review. PubMed PMID: 9362434.

205: Berenson JR. Bisphosphonates in multiple myeloma. Cancer. 1997 Oct 15;80(8 Suppl):1661-7. Review. PubMed PMID: 9362433.

206: Walker P, Watanabe S, Lawlor P, Hanson J, Pereira J, Bruera E. Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity. Ann Oncol. 1997 Sep;8(9):915-6. PubMed PMID: 9358945.

207: Fernández-Conde M, Alcover J, Aaron JE, Ordi J, Carretero P. Skeletal response to clodronate in prostate cancer with bone metastases. Am J Clin Oncol. 1997 Oct;20(5):471-6. PubMed PMID: 9345330.

208: Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997 Sep 15;57(18):3890-4. PubMed PMID: 9307266.

209: Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 1997 Sep;98(3):665-72. PubMed PMID: 9332325.

210: Martínez ME, Pastrana P, Sánchez-Cabezudo MJ, Jariego C, Del Campo MT. Effect of clodronate on calcidiol serum levels in women with breast cancer. Calcif Tissue Int. 1997 Aug;61(2):148-50. PubMed PMID: 9236263.

211: Eulry F, Poirier JM, Perard D, Bergamasco P, Lechevalier D, Magnin J. Cauda equina syndrome with pagetic vertebral fusion. Clinical recovery under calcium-vitamin D supplementation plus clodronate after apparent failure of pamidronate and acquired resistance to etidronate. Rev Rhum Engl Ed. 1997 Jul-Sep;64(7-9):495-9. PubMed PMID: 9338932.

212: Teronen O, Konttinen YT, Lindqvist C, Salo T, Ingman T, Lauhio A, Ding Y, Santavirta S, Valleala H, Sorsa T. Inhibition of matrix metalloproteinase-1 by dichloromethylene bisphosphonate (clodronate). Calcif Tissue Int. 1997 Jul;61(1):59-61. Review. PubMed PMID: 9192515.

213: Ernst DS, Brasher P, Hagen N, Paterson AH, MacDonald RN, Bruera E. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage. 1997 Jun;13(6):319-26. PubMed PMID: 9204651.

214: Paterson AH. Should bisphosphonates be standard therapy for bone pain? Support Care Cancer. 1997 May;5(3):200-4. Review. PubMed PMID: 9176965.

215: Saarto T, Blomqvist C, Välimäki M, Mäkelä P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997 Apr;15(4):1341-7. PubMed PMID: 9193325.

216: Slabý J, Spicka I, Hulejová H, Spacek P, Cieslar P, Klener P. [Effect of clodronate in patients with multiple myeloma. Evaluation of specific markers of bone resorption]. Cas Lek Cesk. 1997 Jan 22;136(2):57-60. Czech. PubMed PMID: 9147856.

217: Bankhead C. Bisphosphonates spearhead new approach to treating bone metastases. J Natl Cancer Inst. 1997 Jan 15;89(2):115-6. PubMed PMID: 8998176.

218: Kylmälä T, Taube T, Tammela TL, Risteli L, Risteli J, Elomaa I. Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer. Br J Cancer. 1997;76(7):939-42. PubMed PMID: 9328156; PubMed Central PMCID: PMC2228066.

219: Saarto T, Blomqvist C, Välimäki M, Mäkelä P, Sarna S, Elomaa I. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer. 1997;75(4):602-5. PubMed PMID: 9052418; PubMed Central PMCID: PMC2063321.

220: Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol. 1997 Jan;15(1):131-8. PubMed PMID: 8996134.

221: Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 1996 Dec;19(6):663-7. PubMed PMID: 8968035.

222: Peest D, Deicher H, Fett W, Harms P, Braun HJ, Planker M, Kindler U, Klinkenstein C, Schäfer E, Schumacher K, Siecke H. Pyridinium cross-links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronate therapy--a pilot study of the German Myeloma Treatment Group (GMTG). Eur J Cancer. 1996 Nov;32A(12):2053-7. PubMed PMID: 9014744.

223: Kylmälä T, Castrén-Kortekangas P, Seppänen J, Ylitalo P, Tammela TL. Effect of concomitant administration of clodronate and estramustine phosphate on their bioavailability in patients with metastasized prostate cancer. Pharmacol Toxicol. 1996 Sep;79(3):157-60. PubMed PMID: 8884875.

224: Lehmann T, Beyeler C, Lämmle B, Hunziker T, Vock P, Olah AJ, Dahinden C, Gerber NJ. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol. 1996 Sep;35(9):898-900. PubMed PMID: 8810675.

225: Body JJ, Coleman RE, Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev. 1996 Jul;22(4):265-87. Review. PubMed PMID: 9025784.

226: Bauduer F, Delmer A. [Multiple myeloma and bone manifestations. Role of clodronate]. Bull Cancer. 1996 Jul;83(7):542-7. Review. French. PubMed PMID: 8868941.

227: Adam Z, Prokes B, Znojĭl V, Vorlícek J, Hejlová N, Hájek D, Krejcí M. [The effect of clodronate on bone density in patients with multiple myeloma--a 2-year follow-up of therapeutic effects]. Vnitr Lek. 1996 Jun;42(6):379-85. Czech. PubMed PMID: 8928406.

228: Rizzoli R, Forni M, Schaad MA, Slosman DO, Sappino AP, Garcia J, Bonjour JP. Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Bone. 1996 Jun;18(6):531-7. PubMed PMID: 8805993.

229: Elomaa I, Risteli L, Laakso M, Lahtinen R, Virkkunen P, Risteli J. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. Eur J Cancer. 1996 Jun;32A(7):1166-70. PubMed PMID: 8758248.

230: Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiebaud D. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone. 1996 Feb;18(2):133-9. PubMed PMID: 8833207.

231: Blomqvist C, Elomaa I. Bisphosphonate therapy in metastatic breast cancer. Acta Oncol. 1996;35 Suppl 5:81-3. Review. PubMed PMID: 9142974.

232: Kanis JA. Rationale for the use of bisphosphonates in breast cancer. Acta Oncol. 1996;35 Suppl 5:61-7. Review. PubMed PMID: 9142969.

233: Laakso M, Jantunen E. Bisphosphonate therapy in multiple myeloma. Acta Oncol. 1996;35 Suppl 5:55-6. Review. PubMed PMID: 9142966.

234: Strang P. Analgesic effect of bisphosphonates on bone pain in breast cancer patients: a review article. Acta Oncol. 1996;35 Suppl 5:50-4. Review. PubMed PMID: 9142965.

235: Bessmel'tsev SS, Abdulkadyrov KM. [Skeletal bone lesion and the effectiveness of Bonephos (clodronate) in the comprehensive therapy of multiple myeloma]. Vopr Onkol. 1996;42(4):12-8. Review. Russian. PubMed PMID: 8928450.

236: Ushio Y, Yamamoto N, Sanchez-Bueno A, Yoshida R. Failure to reject an allografted tumor after elimination of macrophages in mice. Microbiol Immunol. 1996;40(7):489-98. PubMed PMID: 8865154.

237: Moiseenko VM, Blinov NN. [Metastatic bone lesions in solid tumors and possible use of clodronate (Bonephos) in clinical oncology]. Vopr Onkol. 1996;42(2):17-30. Review. Russian. PubMed PMID: 8815629.

238: Gallacher SJ. Formulary management of drugs for cancer-associated hypercalcaemia. Pharmacoeconomics. 1996 Jan;9(1):39-50. Review. PubMed PMID: 10160086.

239: Paterson AH, Kanis JA, Powles TJ, McCloskey E, Hanson J, Ashley S. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. Can J Oncol. 1995 Dec;5 Suppl 1:54-7. PubMed PMID: 8853526.

240: Kawachi Y, Arai K, Moroda T, Kawamura T, Umezu H, Naito M, Ohtsuka K, Hasegawa K, Takahashi-Iwanaga H, Iwanaga T, et al. Supportive cellular elements for hepatic T cell differentiation: T cells expressing intermediate levels of the T cell receptor are cytotoxic against syngeneic hepatoma, and are lost after hepatocyte damage. Eur J Immunol. 1995 Dec;25(12):3452-9. PubMed PMID: 8566037.

241: Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer. 1995 Nov;72(5):1289-93. PubMed PMID: 7577484; PubMed Central PMCID: PMC2033943.

242: Jantunen E, Lahtinen R, Laakso M. Use of clodronate in multiple myeloma. Leuk Lymphoma. 1995 Oct;19(3-4):207-11. Review. PubMed PMID: 8535211.

243: Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol. 1995 Sep;13(9):2427-30. PubMed PMID: 7666103.

244: Cresswell SM, English PJ, Hall RR, Roberts JT, Marsh MM. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol. 1995 Sep;76(3):360-5. PubMed PMID: 7551847.

245: Kanis JA. Bone and cancer: pathophysiology and treatment of metastases. Bone. 1995 Aug;17(2 Suppl):101S-105S. Review. PubMed PMID: 8579890.

246: O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol. 1995 Apr;13(4):929-34. PubMed PMID: 7707121.

247: Koyano H, Schimizu T, Shishiba Y. The bisphosphonate dilemma. J Nucl Med. 1995 Apr;36(4):705-6. PubMed PMID: 7699469.

248: Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamäki A, Tienhaara A, Laakso M, Lahtinen R. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood. 1995 Feb 1;85(3):765-71. PubMed PMID: 7530507.

249: Jantunen E, Lahtinen R, Laakso M. [Clodronate and myeloma]. Duodecim. 1995;111(12):1085-7. Review. Finnish. PubMed PMID: 9213542.

250: Elomaa I, Blomqvist C. Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy. Acta Oncol. 1995;34(5):629-36. Review. PubMed PMID: 7546830.

251: Adam Z, Prokes B, Hájek D, Vorlícek J. Increasing bone density in myeloma patients after the administration of clodronate. Acta Med Austriaca. 1995;22(1-2):9-12. PubMed PMID: 7544057.

252: Dunn CJ, Fitton A, Sorkin EM. Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging. 1994 Dec;5(6):446-74. Review. PubMed PMID: 7858370.

253: Adam Z, Prokes B, Hájek D, Vorlícek J, Tomíska M, Hájek J, Penka M, Mayer J, Hejlová N. [Increased bone density in patients with multiple myeloma treated with clodronate]. Vnitr Lek. 1994 Nov;40(11):726-9. Czech. PubMed PMID: 7810097.

254: Jaspers C, Bauer R, König E, Lederbogen S, Reinwein D. [An unusual course of severe osteoporosis]. Internist (Berl). 1994 Oct;35(10):934-6. German. PubMed PMID: 8002229.

255: Laakso M, Lahtinen R, Virkkunen P, Elomaa I. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Br J Haematol. 1994 Aug;87(4):725-9. PubMed PMID: 7986713.

256: Plosker GL, Goa KL. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs. 1994 Jun;47(6):945-82. Review. PubMed PMID: 7521833.

257: Bondiau PY, Peyrade F, Creisson A, Pivot X, Lagrange JL, Thyss A. [Severe hypocalcemia after treatment with diphosphonates and aminoglycosides]. Presse Med. 1994 Apr 30-May 7;23(17):816. French. PubMed PMID: 8078844.

258: Voigtmann R, Kirstein A. [Clodronate in treatment of tumor osteopathy. Evaluation in tumor patients with bone metastases or hypercalcemia]. Fortschr Med. 1994 Feb 10;112(4):43-6. German. PubMed PMID: 7512066.

259: Ralston SH. Pathogenesis and management of cancer associated hypercalcaemia. Cancer Surv. 1994;21:179-96. Review. PubMed PMID: 8564993.

260: Kiełbiński M. [Pharmacologic therapy of bone tissue changes due to hematologic malignancies and bone metastasis]. Acta Haematol Pol. 1994;25(2):91-8. Review. Polish. PubMed PMID: 8067192.

261: Mason MD, Glaholm J, Dearnaley DP. The use of bisphosphonates in prostatic cancer. Clin Oncol (R Coll Radiol). 1994;6(2):77-8. PubMed PMID: 8018576.

262: Taube T, Kylmälä T, Lamberg-Allardt C, Tammela TL, Elomaa I. The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study. Eur J Cancer. 1994;30A(6):751-8. PubMed PMID: 7917532.

263: Mönkkönen J, Taskinen M, Auriola SO, Urtti A. Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro. J Drug Target. 1994;2(4):299-308. PubMed PMID: 7858955.

264: Kylmälä T, Tammela TL, Lindholm TS, Seppänen J. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann Chir Gynaecol. 1994;83(4):316-9. PubMed PMID: 7537482.

265: Beghé F, Luzzani M. A new schedule for clodronate treatment in patients with breast cancer and bone metastases. Ann N Y Acad Sci. 1993 Nov 30;698:367-71. PubMed PMID: 8279777.

266: Su RJ, Chang CC, Tsai KS. Plasma PTH and PTH-rP levels and clodronate therapy in cancer patients with hypercalcemia. J Formos Med Assoc. 1993 Nov;92(11):977-82. PubMed PMID: 7910069.

267: Vorreuther R. Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. Br J Urol. 1993 Nov;72(5 Pt 2):792-5. PubMed PMID: 7506626.

268: Krempien B, Manegold C. Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphonate Cl2MBP. Cancer. 1993 Jul 1;72(1):91-8. PubMed PMID: 8508433.

269: Heuff G, Oldenburg HS, Boutkan H, Visser JJ, Beelen RH, Van Rooijen N, Dijkstra CD, Meyer S. Enhanced tumour growth in the rat liver after selective elimination of Kupffer cells. Cancer Immunol Immunother. 1993 Jul;37(2):125-30. PubMed PMID: 8319242.

270: Pecherstorfer M, Schilling T, Janisch S, Woloszczuk W, Baumgartner G, Ziegler R, Ogris E. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med. 1993 Jul;34(7):1039-44. PubMed PMID: 8315476.

271: Hayes D, Condon F, Henry M, Duggan M, Mitchell T. Sodium clodronate in a patient with the Eisenmenger syndrome, hyperparathyroidism and multiple endocrine adenomatosis. Ir Med J. 1993 Jul-Aug;86(4):133. PubMed PMID: 8103043.

272: Badertscher E, Warnica JW, Ernst DS. Acute hypercalcemia and severe bradycardia in a patient with breast cancer. CMAJ. 1993 May 1;148(9):1506-8. PubMed PMID: 8477369; PubMed Central PMCID: PMC1491861.

273: Mayordomo JI, Rivera F. Severe hypocalcaemia after treatment with oral clodronate and aminoglycoside. Ann Oncol. 1993 May;4(5):432-3. PubMed PMID: 8353080.

274: Clemens MR, Fessele K, Heim ME. Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann Hematol. 1993 Mar;66(3):141-6. PubMed PMID: 8471660.

275: O'Rourke NP, McCloskey EV, Vasikaran S, Eyres K, Fern D, Kanis JA. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer. 1993 Mar;67(3):560-3. PubMed PMID: 8439504; PubMed Central PMCID: PMC1968276.

276: Wasan HS, Waxman J. Clodronate for multiple myeloma. Lancet. 1993 Jan 16;341(8838):175-6. PubMed PMID: 8093768.

277: Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993 Jan;11(1):59-65. PubMed PMID: 8418243.

278: Taube T, Elomaa I, Blomqvist C, Beneton MN, Kanis JA. Comparative effects of clodronate and calcitonin on bone in metastatic breast cancer: a histomorphometric study. Eur J Cancer. 1993;29A(12):1677-81. PubMed PMID: 8398293.

279: Abdulkadyrov KM, Bessmel'tsev SS. [The use of the preparation bonefos in the combined therapy of multiple myeloma patients]. Ter Arkh. 1993;65(12):70-2. Russian. PubMed PMID: 8146779.

280: Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. [Double-blind trial of oral clodronate in breast cancer patients with bone metastases]. Bull Cancer. 1993;80(10 Suppl):50-6. French. PubMed PMID: 8081032.

281: Kylmälä T, Tammela T, Risteli L, Risteli J, Taube T, Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer. 1993;29A(6):821-5. PubMed PMID: 7683480.

282: Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet. 1992 Oct 31;340(8827):1049-52. Erratum in: Lancet 1992 Dec 5;340(8832):1420. PubMed PMID: 1357451.

283: Sun YC, Geldof AA, Newling DW, Rao BR. Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates. J Urol. 1992 Oct;148(4):1270-3. PubMed PMID: 1404658.

284: Supportive care drug studies: some promising, some not. Oncology (Williston Park). 1992 Sep;6(9):93-4. PubMed PMID: 1333264.

285: Prier A. [Biphosphonates. Contribution to the treatment of malignant osteolysis]. Presse Med. 1992 Jul 4-11;21(25):1143-5. Review. French. PubMed PMID: 1409460.

286: Puolijoki H, Liippo K. Symptomatic hypercalcaemia in lung cancer. Respir Med. 1992 Jul;86(4):359-60. PubMed PMID: 1448594.

287: Warneke G, Henning HV. [Bisphosphonates. Drugs for the treatment of disorders of calcium and bone metabolism]. Internist (Berl). 1992 Jun;33(6):441-5. Review. German. PubMed PMID: 1385800.

288: Lortholary A, Alleaume C, Pein F, Larra F. [Osteolytic metastases of breast cancer and biphosphonates]. Rev Med Interne. 1992 May-Jun;13(3):238-42. Review. French. PubMed PMID: 1410908.

289: Francini G, Gonnelli S, Petrioli R, Conti F, Paffetti P, Gennari C. Treatment of bone metastases with dichloromethylene bisphosphonate. J Clin Oncol. 1992 Apr;10(4):591-8. PubMed PMID: 1532198.

290: Neri B, Gemelli MT, Sambataro S, Colombi L, Benvenuti F, Ludovici M, Pacini P. Subjective and metabolic effects of clodronate in patients with advanced breast cancer and symptomatic bone metastases. Anticancer Drugs. 1992 Apr;3(2):87-90. Erratum in: Anticancer Drugs 1992 Dec;3(6):696. PubMed PMID: 1388063.

291: Rizzoli R, Buchs B, Bonjour JP. Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate. Int J Cancer. 1992 Mar 12;50(5):706-12. PubMed PMID: 1531972.

292: Vorreuther R, Klotz T, Engelking R. [Clodronate in the palliative therapy of bone-metastasized prostatic carcinoma]. Urologe A. 1992 Mar;31(2):63-6. German. PubMed PMID: 1373255.

293: Ernst DS, MacDonald RN, Paterson AH, Jensen J, Brasher P, Bruera E. A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage. 1992 Jan;7(1):4-11. PubMed PMID: 1531673.

294: Rotstein S, Glas U, Eriksson M, Pfeiffer P, Hansen J, Söderqvist J, Bandmann U, Strid S. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases--a prospective randomised placebo-controlled multicentre study. Eur J Cancer. 1992;28A(4-5):890-3. PubMed PMID: 1388038.

295: Elomaa I, Kylmälä T, Tammela T, Viitanen J, Ottelin J, Ruutu M, Jauhiainen K, Ala-Opas M, Roos L, Seppänen J, et al. Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer. Int Urol Nephrol. 1992;24(2):159-66. PubMed PMID: 1385586.

296: Coleman RE. Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy. Oncology (Williston Park). 1991 Aug;5(8):55-60; discussion 60-2, 65. PubMed PMID: 1834153.

297: Fitton A, McTavish D. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs. 1991 Feb;41(2):289-318. Review. Erratum in: Drugs 1992 Feb;43(2):145. PubMed PMID: 1709854.

298: Diel IJ. [Current possibilities in the therapy and prevention of bone metastases in breast carcinoma?]. Zentralbl Gynakol. 1991;113(19):1023-4. German. PubMed PMID: 1835815.

299: Burki F. New French studies of clodronate in cancer-induced osteolysis. Bone. 1991;12 Suppl 1:S35. PubMed PMID: 1835399.

300: Delmas PD. The use of clodronate in multiple myeloma. Bone. 1991;12 Suppl 1:S31-4. Review. PubMed PMID: 1835398.

301: Bonjour JP, Rizzoli R. Treatment of hypercalcaemia of malignancy with clodronate. Bone. 1991;12 Suppl 1:S19-23. Review. PubMed PMID: 1835397.

302: Pouillart P, Beuzeboc P. [Value of Clodronate in the treatment of bone metastasis]. Bull Cancer. 1991;78(8):737-41. French. PubMed PMID: 1834287.

303: Martoni A, Guaraldi M, Camera P, Biagi R, Marri S, Beghé F, Pannuti F. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology. 1991;48(2):97-101. PubMed PMID: 1825515.

304: Conte N, Di Virgilio R, Da Rin G, Roiter I, Pavan P, Legovini P, Foscolo G. Clodronate treatment increases serum osteocalcin in normocalcemic osteolytic bone metastases. Oncology. 1991;48(1):54-7. PubMed PMID: 1824799.

305: Powles T. Clodronate: the potential for the future. Bone. 1991;12 Suppl 1:S43-4. PubMed PMID: 1720014.

306: Biermann WA, Cantor RI, Fellin FM, Jakobowski J, Hopkins L, Newbold RC 3rd. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone. Bone. 1991;12 Suppl 1:S37-42. Review. PubMed PMID: 1720013.

307: Paterson AH, Ernst DS, Powles TJ, Ashley S, McCloskey EV, Kanis JA. Treatment of skeletal disease in breast cancer with clodronate. Bone. 1991;12 Suppl 1:S25-30. Review. PubMed PMID: 1720012.

308: Warrell RP Jr. Hypercalcemia and bone metastases in breast cancer. Curr Opin Oncol. 1990 Dec;2(6):1097-103. Review. PubMed PMID: 2151596.

309: Botturi M, Zanni D, Tosi G. [Drug therapy with disodium clodronate combined with radiotherapy of bone metastasis of solid tumors]. Radiol Med. 1990 Nov;80(5):726-33. Italian. PubMed PMID: 2148401.

310: Caulin F. [Role and use of biphosphonates in the treatment of metastatic breast cancer]. Pathol Biol (Paris). 1990 Oct;38(8):862-3. French. PubMed PMID: 2148817.

311: Caristi N, Russi EG, Adamo V, Altavilla G, d'Aquino A, Delia P, Di Carlo M, Maisano R, Romeo F, Salvi L. [Clodronate and radiotherapy for the treatment of osteolysis caused by metastasis of breast carcinoma and non-small cell lung carcinoma. A retrospective study]. G Ital Oncol. 1990 Oct-Dec;10(4):129-32. Italian. PubMed PMID: 1965506.

312: Ralston SH, Gallacher SJ, Patel U, Fraser WD, Dryburgh FJ, Boyle IT. Use of bisphosphonates in hypercalcaemia due to malignancy. Lancet. 1990 Mar 24;335(8691):737. PubMed PMID: 1969100.

313: Kanis JA, McCloskey EV, Paterson AH. Use of diphosphonates in hypercalcaemia due to malignancy. Lancet. 1990 Jan 20;335(8682):170-1. PubMed PMID: 1967461.

314: Harjung H, Fritze D. [Monotherapy with clodronate for tumor-induced hypercalcemia]. Dtsch Med Wochenschr. 1990 Jan 12;115(2):48-52. German. PubMed PMID: 2136827.

315: Luzzani M, Vidili MG, Rissotto R, Nobile MT, Beghè F, Rosso R, Gottlieb A. Disodium clodronate in the treatment of pain due to bone metastases. Int J Clin Pharmacol Res. 1990;10(4):243-6. PubMed PMID: 2150406.

316: Bonjour JP, Rizzoli R. Clodronate in hypercalcemia of malignancy. Calcif Tissue Int. 1990;46 Suppl:S20-5. Review. PubMed PMID: 2137362.

317: Merlini G, Parrinello GA, Piccinini L, Crema F, Fiorentini ML, Riccardi A, Pavesi F, Novazzi F, Silingardi V, Ascari E. Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol. 1990 Jan-Feb;8(1):23-30. PubMed PMID: 2137106.

318: Hanhijärvi H, Elomaa I, Karlsson M, Lauren L. Pharmacokinetics of disodium clodronate after daily intravenous infusions during five consecutive days. Int J Clin Pharmacol Ther Toxicol. 1989 Dec;27(12):602-6. PubMed PMID: 2533182.

319: Ralston SH, Gallacher SJ, Patel U, Dryburgh FJ, Fraser WD, Cowan RA, Boyle IT. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet. 1989 Nov 18;2(8673):1180-2. PubMed PMID: 2572902.

320: Mazzarino C, Nicosia A, Garraffo C, Tantillo F, Monte V, Girlando A, Malaponte G. Interleukin-2 receptors in patients with lung carcinoma metastasis undergoing treatment with disodium-clodronate. Preliminary research. J Chemother. 1989 Jul;1(4 Suppl):1198-201. PubMed PMID: 16312832.

321: Pentikäinen PJ, Elomaa I, Nurmi AK, Kärkkäinen S. Pharmacokinetics of clodronate in patients with metastatic breast cancer. Int J Clin Pharmacol Ther Toxicol. 1989 May;27(5):222-8. PubMed PMID: 2525532.

322: Ascari E, Attardo-Parrinello G, Merlini G. Treatment of painful bone lesions and hypercalcemia. Eur J Haematol Suppl. 1989;51:135-9. PubMed PMID: 2534078.

323: Adami S, Mian M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res. 1989;116:67-72. PubMed PMID: 2527401.

324: Ziegler R, Scharla SH. Treatment of tumor hypercalcemia with clodronate. Recent Results Cancer Res. 1989;116:46-53. PubMed PMID: 2527400.

325: Ljunghall S. Use of clodronate and calcitonin in hypercalcemia due to malignancy. Recent Results Cancer Res. 1989;116:40-5. Review. PubMed PMID: 2527399.

326: Decker JE, Morrison NE, Lorenzo JA, Samour CM, McCarron BA, Raisz LG. The effects of thionapthene-2-carboxylic acid-lysine on the hypercalcemia of malignancy in the rat. Calcif Tissue Int. 1989 Jan;44(1):61-4. PubMed PMID: 2521808.

327: Sartori L, Insogna KL, Barrett PQ. Renal phosphate transport in humoral hypercalcemia of malignancy. Am J Physiol. 1988 Dec;255(6 Pt 2):F1078-84. PubMed PMID: 2974244.

328: Conte N, Breda F, Di Virgilio R, Legovini P, Roiter I, Foscolo G, Caenaro G. [Diphosphonates and primary hyperparathyroidism]. Ann Ital Med Int. 1988 Oct-Dec;3(4):278-82. Italian. PubMed PMID: 2978945.

329: Pollard M, Luckert PH, Scheu J. Effects of diphosphonate and x-rays on bone lesions induced in rats by prostate cancer cells. Cancer. 1988 May 15;61(10):2027-32. PubMed PMID: 2965968.

330: Elomaa I, Blomqvist C, Porkka L, Holmström T, Taube T, Lamberg-Allardt C, Borgström GH. Clodronate for osteolytic metastases due to breast cancer. Biomed Pharmacother. 1988;42(2):111-6. PubMed PMID: 2971403.

331: Bonjour JP, Philippe J, Guelpa G, Bisetti A, Rizzoli R, Jung A, Rosini S, Kanis JA. Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone. 1988;9(3):123-30. PubMed PMID: 2971382.

332: van Rooijen N, Kors N, ter Hart H, Claassen E. In vitro and in vivo elimination of macrophage tumor cells using liposome-encapsulated dichloromethylene diphosphonate. Virchows Arch B Cell Pathol Incl Mol Pathol. 1988;54(4):241-5. PubMed PMID: 2895535.

333: Peck WA. Results of a randomized study of clodronate in treating cancer-related hypercalcemia. Arch Intern Med. 1987 Nov;147(11):2056-7. PubMed PMID: 2960292.

334: Rizzoli R, Fleisch H. The Walker 256/B carcinosarcoma in thyroparathyroidectomized rats: a model to evaluate inhibitors of bone resorption. Calcif Tissue Int. 1987 Oct;41(4):202-7. PubMed PMID: 2960427.

335: Attardo-Parrinello G, Merlini G, Pavesi F, Crema F, Fiorentini ML, Ascari E. Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate. Arch Intern Med. 1987 Sep;147(9):1629-33. PubMed PMID: 2957971.

336: Adami S, Bolzicco GP, Rizzo A, Salvagno G, Bertoldo F, Rossini M, Suppi R, Lo Cascio V. The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy. Bone Miner. 1987 Aug;2(5):395-404. PubMed PMID: 2975514.

337: Scharla SH, Minne HW, Sattar P, Mende U, Blind E, Schmidt-Gayk H, Wüster C, Ho T, Ziegler R. [Treatment of tumor hypercalcemia with clodronate. Effect on parathormone and calcitriol]. Dtsch Med Wochenschr. 1987 Jul 10;112(28-29):1121-5. German. PubMed PMID: 2956079.

338: Witte RS, Koeller J, Davis TE, Benson AB 3rd, Durie BG, Lipton A, Stock JL, Citrin DL, Jacobs TP. Clodronate. A randomized study in the treatment of cancer-related hypercalcemia. Arch Intern Med. 1987 May;147(5):937-9. PubMed PMID: 2953318.

339: Lind L, Wengle B, Ljunghall S. Treatment with clodronate in patients with hypercalcemia secondary to malignancy. Ups J Med Sci. 1987;92(3):259-63. PubMed PMID: 2966487.

340: Ljunghall S, Rastad J, Akerström G. Comparative effects of calcitonin and clodronate in hypercalcaemia. Bone. 1987;8 Suppl 1:S79-83. PubMed PMID: 2961359.

341: Canfield RE, Siris ES, Jacobs TP. Dichloromethylene diphosphonate action in hematologic and other malignancies. Bone. 1987;8 Suppl 1:S57-62. PubMed PMID: 2961356.

342: Elomaa I, Blomqvist C, Porkka L, Lamberg-Allardt C, Borgström GH. Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone. 1987;8 Suppl 1:S53-6. PubMed PMID: 2961355.

343: Urwin GH, Yates AJ, Gray RE, Hamdy NA, McCloskey EV, Preston FE, Greaves M, Neil FE, Kanis JA. Treatment of the hypercalcaemia of malignancy with intravenous clodronate. Bone. 1987;8 Suppl 1:S43-51. PubMed PMID: 2961354.

344: Clodronate--a new perspective in the treatment of neoplastic bone disease. Proceedings of a meeting. Helsinki. Bone. 1987;8 Suppl 1:S1-86. PubMed PMID: 2961353.

345: Rastad J, Benson L, Johansson H, Knuutila M, Pettersson B, Wallfelt C, Akerström G, Ljunghall S. Clodronate treatment in patients with malignancy-associated hypercalcemia. Acta Med Scand. 1987;221(5):489-94. PubMed PMID: 2955674.

346: Borgström GH, Elomaa I, Blomqvist C, Porkka L. Cytogenetic investigations of patients on clodronate therapy for Paget's disease of bone. Bone. 1987;8 Suppl 1:S85-6. PubMed PMID: 2825742.

347: McCloskey EV, Yates AJ, Beneton MN, Galloway J, Harris S, Kanis JA. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone. 1987;8 Suppl 1:S35-41. PubMed PMID: 2825741.

348: Warrell RP Jr. New inhibitors of osteolysis: implications for hypercalcemia and bone metastases. J Clin Oncol. 1986 Aug;4(8):1160-1. PubMed PMID: 3016204.

349: Elte JW, Bijvoet OL, Cleton FJ, van Oosterom AT, Sleeboom HP. Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment. Eur J Cancer Clin Oncol. 1986 Apr;22(4):493-500. Review. PubMed PMID: 2942409.

350: Pollard M, Luckert PH. The beneficial effects of diphosphonate and piroxicam on the osteolytic and metastatic spread of rat prostate carcinoma cells. Prostate. 1986;8(1):81-6. PubMed PMID: 2935791.

351: Coleman RE, Rubens RD. Bone metastases and breast cancer. Cancer Treat Rev. 1985 Dec;12(4):251-70. Review. PubMed PMID: 2938732.

352: Tazume S, Pollard M. The relationship between natural killer cells and drugs that modify metastasis of PA-III cells. Cancer Lett. 1985 Dec;29(3):323-9. PubMed PMID: 2934126.

353: Adami S, Salvagno G, Guarrera G, Bianchi G, Dorizzi R, Rosini S, Mobilio G, Lo Cascio V. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol. 1985 Dec;134(6):1152-4. PubMed PMID: 2932559.

354: Conte N, Di Virgilio R, Roiter I, Foscolo G, Baruffi C. [Neoplastic hypercalcemia with renal insufficiency: treatment with dichloromethylene diphosphonate]. Clin Ter. 1985 Nov 15;115(3):177-80. Italian. PubMed PMID: 2935356.

355: Pollard M, Luckert PH. Effects of dichloromethylene diphosphonate on the osteolytic and osteoplastic effects of rat prostate adenocarcinoma cells. J Natl Cancer Inst. 1985 Nov;75(5):949-54. PubMed PMID: 2932588.

356: Percival RC, Watson ME, Williams JL, Kanis JA. Carcinoma of the prostate: remission of paraparesis with inhibitors of bone resorption. Postgrad Med J. 1985 Jun;61(716):551-3. PubMed PMID: 3160014; PubMed Central PMCID: PMC2418436.

357: Percival RC, Paterson AD, Yates AJ, Beard DJ, Douglas DL, Neal FE, Russell RG, Kanis JA. Treatment of malignant hypercalcaemia with clodronate. Br J Cancer. 1985 May;51(5):665-9. PubMed PMID: 3158326; PubMed Central PMCID: PMC1977044.

358: Conte N, Di Virgilio R, Roiter I, Caberlotto L. Hypercalcemia in malignancies: treatment with dichloromethylene diphosphonate (Cl2MDP). Tumori. 1985 Feb 28;71(1):51-4. PubMed PMID: 3157251.

359: Conte N, Di Virgilio R, Roiter I. [Hypercalcemic crises of myelomatous origin. Treatment with dichloromethylene diphosphonate]. Presse Med. 1984 Nov 24;13(42):2586. French. PubMed PMID: 6239268.

360: Jüngst D. Disodium clodronate effective in management of severe hypercalcaemia caused by parathyroid carcinoma. Lancet. 1984 Nov 3;2(8410):1043. PubMed PMID: 6149425.

361: Delmas PD, Meunier PJ. [Diphosphonates in the treatment of hypercalcemia]. Rev Med Interne. 1984 Nov;5(4):363-6. French. PubMed PMID: 6240753.

362: Peyron R, Sereni D, Grateau G, Boissonnas A, Cremer GA, Laroche C. [Efficacy of intravenous dichloromethylene diphosphonate in paraneoplastic hypercalcemia resistant to mithramycin]. Rev Rhum Mal Osteoartic. 1984 Jul-Sep;51(7-8):435-7. French. PubMed PMID: 6238399.

363: Jung A, Bornand J, Mermillod B, Edouard C, Meunier PJ. Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat. Cancer Res. 1984 Jul;44(7):3007-11. PubMed PMID: 6233002.

364: Elomaa I, Blomqvist C, Porkka L, Holmström T, Laine H. Long-term effects of dichloromethylene diphosphonate in patients with osteolytic bone metastases and coincident primary hyperparathyroidism. Cancer Treat Rep. 1984 Apr;68(4):655-7. PubMed PMID: 6231989.

365: Chantraine A, Jung A, van Ouwenaller C, Donath A. [Dichloromethylene diphosphonate in the treatment of lytic bone metastases]. Presse Med. 1984 Feb 25;13(8):479-82. French. PubMed PMID: 6230629.

366: Conte N, Di Virgilio R, Roiter I. [Preoperative normalization of hypercalcemia, caused by parathyroid cancer, by intravenous administration of dichloromethylene diphosphonate]. Minerva Endocrinol. 1984 Jan-Mar;9(1):47-8. Italian. PubMed PMID: 6239086.

367: Labat ML, Florentin I, Davigny M, Moricard Y, Milhaud G. Dichloromethylene diphosphonate (Cl2MDP) reduces natural killer (NK) cell activity in mice. Metab Bone Dis Relat Res. 1984;5(6):281-7. PubMed PMID: 6238219.

368: Martodam RR, Thornton KS, Sica DA, D'Souza SM, Flora L, Mundy GR. The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat Leydig cell tumor. Calcif Tissue Int. 1983 Jul;35(4-5):512-9. PubMed PMID: 6311375.

369: Jung A, Chantraine A, Donath A, van Ouwenaller C, Turnill D, Mermillod B, Kitler ME. Use of dichloromethylene diphosphonate in metastatic bone disease. N Engl J Med. 1983 Jun 23;308(25):1499-501. PubMed PMID: 6222257.

370: Paterson AD, Kanis JA, Cameron EC, Douglas DL, Beard DJ, Preston FE, Russell RG. The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma. Br J Haematol. 1983 May;54(1):121-32. PubMed PMID: 6221750.

371: Kanis JA, Paterson AD, Russell RG. The use of diphosphonates in myeloma. Br J Haematol. 1983 Apr;53(4):688-90. PubMed PMID: 6219695.

372: Siris ES, Hyman GA, Canfield RE. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med. 1983 Mar;74(3):401-6. PubMed PMID: 6219577.

373: Elomaa I, Blomqvist C, Gröhn P, Porkka L, Kairento AL, Selander K, Lamberg-Allardt C, Holmström T. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet. 1983 Jan 22;1(8317):146-9. PubMed PMID: 6130197.

374: Siris ES, Grossbard L, Halper JP, Blume RS, Jacobs TP. Chronic lymphocytic leukemia and hypercalcemia: treatment with dichloromethylene diphosphonate. Metab Bone Dis Relat Res. 1983-1984;5(2):61-3. PubMed PMID: 6231452.

375: Markkula R, Repo H, Leirisalo M, Blomqvist C, Elomaa I. Effect of dichloromethylene diphosphonate (Cl2MDP) on immune function in breast cancer patients with bone metastases. Cancer Immunol Immunother. 1983;15(2):159-61. PubMed PMID: 6223692.

376: Shane E, Jacobs TP, Siris ES, Steinberg SF, Stoddart K, Canfield RE, Bilezikian JP. Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate. Am J Med. 1982 Jun;72(6):939-44. PubMed PMID: 6211978.

377: Delmas P, Chapuy MC, Vignon E, Briançon D, Charhon S, Meunier PJ. [Dichloromethylene diphosphonate (Cl2MDP) treatment of hypercalcaemia produced from bone metastases (author's transl)]. Nouv Presse Med. 1982 Apr 24;11(19):1471-4. French. PubMed PMID: 6210878.

378: Jung A. Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Am J Med. 1982 Feb;72(2):221-6. PubMed PMID: 6460442.

379: Delmas PD, Charhon S, Chapuy MC, Vignon E, Briancon D, Edouard C, Meunier PJ. Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Relat Res. 1982;4(3):163-8. PubMed PMID: 6218370.

380: Doppelt SH, Slovik DM, Neer RM, Nolan J, Zusman RM, Potts JT Jr. Gut-mediated hypercalcemia in rabbits bearing VX2 carcinoma: new mechanism for tumor-induced hypercalcemia. Proc Natl Acad Sci U S A. 1982 Jan;79(2):640-4. PubMed PMID: 6210910; PubMed Central PMCID: PMC345802.

381: Jung A, Fleisch H. [Diphosphonates in the treatment of bone metastases]. Schweiz Med Wochenschr. 1981 Dec 5;111(49):1878-82. French. PubMed PMID: 6460313.

382: Tschopp JM, Jung A, Miescher PA. [Suppression of severe hypocalcemia associated with malignant lymphoma by intravenous administration of dichloromethylene diphosphonate]. Schweiz Med Wochenschr. 1981 Oct 31;111(44):1655-7. French. PubMed PMID: 6458087.

383: Jung A, van Ouwenaller C, Chantraine A, Courvoisier B. Parenteral diphosphonates for treating malignant hypercalcemia. Cancer. 1981 Oct 15;48(8):1922-5. PubMed PMID: 6456809.

384: Jung A, van Ouwenaller C, Chantraine A, Donath A, Rosini S. Use of dichloromethylene diphosphonate in metastatic bone disease. N Engl J Med. 1981 Aug 6;305(6):343-4. PubMed PMID: 6454076.

385: Jung A, Mermillod B, Barras C, Baud M, Courvoisier B. Inhibition by two diphosphonates of bone lysis in tumor-conditioned media. Cancer Res. 1981 Aug;41(8):3233-7. PubMed PMID: 6454481.

386: Cohen AI, Koeller J, Davis TE, Citrin DL. Iv dichloromethylene diphosphonate in cancer-associated hypercalcemia: a phase I-II evaluation. Cancer Treat Rep. 1981 Jul-Aug;65(7-8):651-3. PubMed PMID: 6454484.

387: Vergnon JM, Cheix F, Vauzelle JL, Charhon S, Meunier PJ. [Multifocal sarcoma associated with Paget's disease of bone. Effects of dichloromethylene diphosphate (author's transl)]. Nouv Presse Med. 1981 Jun 27;10(28):2353-4, 2359-60. French. PubMed PMID: 6455648.

388: Jacobs TP, Siris ES, Bilezikian JP, Baquiran DC, Shane E, Canfield RE. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate. Ann Intern Med. 1981 Mar;94(3):312-6. PubMed PMID: 6452846.

389: Douglas DL, Duckworth T, Russell RG, Kanis JA, Preston CJ, Preston FE, Prenton MA, Woodhead JS. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet. 1980 May 17;1(8177):1043-7. PubMed PMID: 6103389.

390: Chapuy MC, Meunier PJ, Alexandre CM, Vignon EP. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases. J Clin Invest. 1980 May;65(5):1243-7. PubMed PMID: 6444955; PubMed Central PMCID: PMC371459.

391: Raisz LG. New diphosphonates to block bone resorption. N Engl J Med. 1980 Feb 7;302(6):347-8. PubMed PMID: 6444242.

392: Siris ES, Sherman WH, Baquiran DC, Schlatterer JP, Osserman EF, Canfield RE. Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N Engl J Med. 1980 Feb 7;302(6):310-5. PubMed PMID: 6444241.

393: Jung A, Barras C, Mermillod B, Courvoisier B. [Effect of 2 phosphonates on the osteolysis induced by tumor extracts]. Schweiz Med Wochenschr. 1979 Dec 8;109(47):1888-90. French. PubMed PMID: 161073.